KaliVir Immunotherapeutics, Inc. has introduced its state-of-the-art Good Manufacturing Practice (GMP) cleanroom facility. 

This facility is dedicated to the manufacturing of KaliVir's pipeline of oncolytic viruses, with the successful completion of the inaugural manufacturing run for its lead clinical candidate, VET3-TGI.

Spanning over 1,000 square feet, KaliVir's GMP manufacturing facility is equipped with cutting-edge technology, including the iCellis 500 bioreactor, hyperstack, filtration, and chromatography capabilities. The facility is further supported by KaliVir’s comprehensive quality, process development, and analytical development capabilities, ensuring adherence to the highest manufacturing standards.

Notably, KaliVir Immunotherapeutics is not only focused on advancing its own oncolytic viruses but also offers production services for select biotechnology companies globally. This marks a strategic capability to contribute to the broader landscape of biotech research and development.

Steve Thorne, Ph.D., Chief Scientific Officer, and founder of KaliVir Immunotherapeutics expressed the significance of the GMP facility, stating, "The opening of our GMP facility marks a pivotal moment in our journey to advance transformative cancer therapies. This state-of-the-art facility underscores our dedication to meeting the highest manufacturing standards and ensuring the seamless development of groundbreaking oncolytic viral immunotherapies from conception to the clinic. We are proud of the progress we've made and excited about the potential impact our innovative treatments can have in the fight against cancer."

The announcement reflects KaliVir's commitment to excellence in manufacturing and the advancement of oncolytic viral immunotherapies.